The role of tumour-expressed CCR6 and CCR7 in breast cancer metastasis and tumour immunity
This project aims to investigate the role of tumour-expressed CCR6 and CCR7 in breast cancer metastasis and in the anti-tumour immune response in the lymph node. EO771 murine breast cancer cell-line was modified to express the CCL20 chemokine receptor CCR6 or a receptor for the chemokine CCL21, C...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Final Year Project |
Language: | English |
Published: |
Nanyang Technological University
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/139768 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Summary: | This project aims to investigate the role of tumour-expressed CCR6 and CCR7 in
breast cancer metastasis and in the anti-tumour immune response in the lymph
node. EO771 murine breast cancer cell-line was modified to express the CCL20
chemokine receptor CCR6 or a receptor for the chemokine CCL21, CCR7. Data
support that CCR6 can mediate survival signals in human breast cancer cells, while
CCR7 is known to drive lymph node tumour metastasis. Constitutive expression of
CCR6 and CCR7 in modified EO771 was confirmed in vitro and in vivo. Neither
CCR6 nor CCR7 upregulation, with and without ligand addition significantly affected
cell proliferation or apoptosis in normal culture conditions. Preliminary studies with
the CCR7+ EO771 in vivo showed promoted metastasis to tumour-draining lymph
nodes, with 80% of the analysed samples forming tumour foci in the B-cell area.
Immunofluorescence analyses detected regulatory T-cells within all tumour foci
analysed and indicated that PD-L1 was upregulated in T-cell areas close to the
tumour foci. The latter observations suggest that metastasizing tumour cells alter the
anti-tumour response. In summary, the present study lay a foundation for future
research elucidating the roles of tumour-expressed CCR6 and CCR7 in lymph node
metastasis, tumour survival and anti-tumour immunity. |
---|